

Table SI. Clinical variables evaluated

Demographic data	Age (years), sex, profession
Predominant type of urticaria	Acute urticaria, chronic urticaria, chronic inducible urticaria
Presence of angioedema	
Concomitant CIndU	Demographic urticaria, delay pressure urticaria, cholinergic urticaria, cold contact urticaria, heat contact urticaria, solar urticaria, vibratory urticaria, AQuagenic urticaria, contact urticaria, exercise-induced anaphylaxis/urticaria
Disease history	Total disease duration (months), number of episodes during the patient's life, mean time until the first visit (months), duration of current episode (months)
Disease activity	Urticaria Activity Score, Urticaria Activity Score 7, Urticaria Activity Score 3 weeks
Personal history and comorbidities	Drug and alcohol intake, atopy, urticaria, thyroid diseases, rheumatological and autoimmune disorders, infections, digestive system disorders, psychiatric diseases, diabetes mellitus/endocrine disorders, hypertension and other renal disorders, cardiovascular diseases, gynaecological diseases, haematological diseases, genetic disorders, other dermatological diseases, benign and malignant neoplasms
Triggering/exacerbating factors	Infections, stress, insect bite, drugs prescribed drugs, food, systemic disease

CIndU: concomitant inducible urticaria.

Table SII. Laboratory parameters and other diagnostic tests

Laboratory workup (units) [normal values range]		Other tests
Cell blood count		ASST
Kidney function test	Urea (mg/dl) [10–50] Creatinine (mg/dl) [0.5–1.2] Glomerular filtration rate (ml/min/1.73 m ²) [>60]	APST
Liver function test	Bilirubin (mg/dl) [0.2–1.2] Liver enzymes (ALT (UI/l 37C) [7–31], AST (UI/l 37C) [10–32] Gamma glutamyl transpeptidase (GGT) (UI/l 37C) [8–61] Phosphatase alkaline (UI/l 37C) [35–104]	Basophil Activation Test
Lipid profile	Cholesterol (mg/dl) [120–200]	Skin biopsy
Acute-phase reactants	Erythrocyte sedimentation rate (mm/h) [0–12] C-reactive protein (mg/dl) [0–0.8] Ferritin (ng/ml) [13–150] Rheumatoid factor (U/ml) [0.01–20]	Parasites in faeces
Thyroid function	Thyroid hormone test (triiodothyronine (pg/ml) [2.0–4.4] Thyroxin (ng/dl) [0.72–1.7] Thyroid-stimulating hormone (mcU/ml) [0.35–5] Anti-thyroid peroxidase antibodies (UI/ml) [0.1–35] Anti-thyroglobulin antibodies (UI/ml) [0.1–40]	Helicobacter pylori breath test
Other laboratory parameters	IgE (kU/l) [0–100] D-dimer (ng/ml) [0–150]	Patch test
Immunologic profile	Antinuclear antibodies Anti-DNA ds (UI/ml) [0.1–300] Complement system (C4 (mg/dl) [10–40], CH50 (U/ml))	Specific IgE

ASST: Autologous Serum Skin Test; APST: Autologous Plasma Skin Test.

Table SIII. List of variables evaluated in the multivariate analysis (n = 41)

Urticaria Activity Score 7	Omalizumab treatment
Level of treatment	Erythrocyte sedimentation rate
Evolution time	Basophil count
Age	Eosinophil count
Sex	Thyroid-stimulating hormone
Number of episodes during the patient's life	Total triiodothyronine
Angioedema	Free triiodothyronine
IgE serum levels	Free thyroxine
D-dimer serum levels	Anti-thyroid peroxidase antibodies
Atopy	Anti-thyroglobulin antibodies
Contact dermatitis	Antinuclear antibodies
Drug and alcohol intake	C-reactive protein
Rheumatological diseases	Specific IgE
Autoimmune diseases	Helicobacter pylori infection
Thyroid diseases	Parasites in faeces
Hypertension	Autologous serum skin test (erythema)
Diabetes mellitus	Autologous serum skin test (wheal)
Gastrointestinal disorders	Autologous plasma skin test (erythema)
Psychiatric disorders	Autologous plasma skin test (wheal)
Surgical implants	CD63
Other skin diseases	

Table SIV. Notable laboratory findings

Variables (units)	All patients <i>n</i> (%)**	Isolated CSU <i>n</i> (%)	CSU-CIndU <i>n</i> (%)	<i>p</i> -value*
Phosphatase alkaline (> 110 UI/l)	129/405 (31.9)	106/324 (32.7)	23/81 (28.4)	0.4553
Anti-thyroid peroxidase antibodies (> 45 U/ml)	77/378 (20.4)	65/296 (22.0)	12/82 (14.6)	0.1450
Anti-thyroglobulin antibodies (> 50 U/ml)	46/373 (12.3)	40/291 (13.7)	6/82 (7.3)	0.1179
Antinuclear antibodies (1/> 40)	48/155 (31.0)	41/122 (33.6)	7/33 (21.2)	0.1719
IgE (> 100 kU/l)	185/418 (44.3)	141/330 (42.7)	44/88 (50)	0.2223
D-dimer (> 300 ng/ml)	29/92 (31.5)	21/69 (30.4)	8/23 (34.8)	0.6975

**p*-value corresponds to the comparison between isolated-chronic spontaneous urticaria (CSU) and CSU with concomitant inducible urticaria (CSU-CindU) subgroups. **Variable sample size depending on availability of the result of each test.

Table SV. Treatments prescribed in patients with chronic spontaneous urticaria (CSU) (single or combined treatments)

	CSU n/total n (%)
Anti-leukotrienes	3/516 (0.6)
Partial response	3/3 (100)
Complete response	0/3 (0)
Corticosteroids	141/516 (27.3)
Partial response	124/141 (88.0)
Complete response	17/141 (12.0)
Omalizumab	11/516 (2.1)
Partial response	1/11 (9.1)
Complete response	10/11 (90.9)
Cyclosporine A	58/516 (11.2)
Partial response	14/58 (24.1)
Complete response	44/58 (75.9)
Sulfone	13/516 (2.5)
Partial response	9/13 (69.2)
Complete response	4/13 (30.8)